1. This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies. Learn More.
  2. 'News In Brief' for w/c 12th March is now available. Click here to read.
    Dismiss Notice

Phase III Rituximab Trial - News

Discussion in 'BioMedical ME/CFS News' started by Scarecrow, Nov 21, 2017.

  1. Jo Best

    Jo Best Senior Member (Voting Rights)

    Likes Received:
  2. Sasha

    Sasha Senior Member (Voting Rights)

    Likes Received:
    That's 2,200 words, which is a big read for a lot of PWME. The gist seems to be that in the light of the null results from the Norwegian rtx trial, IiME won't be doing a rtx trial and has about £350,000 remaining in its rtx pot, after having spent some of it on B-cell work at UCL. That pot will now be spent on other biomedical research, as yet unspecified. But, given that some of that appears to have been pledges for the rtx trial, it's not clear to me how much of that £350,000 pot is actual cash and whether any pledges might now be withdrawn.

    The relevant bit is right at the bottom:


Share This Page